ClinicalTrials.gg
CompletedNCT05984134Updated Jun 21, 2024

Efficacy and Safety Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction

A Phase 2 interventional study of NL005 Middle Dose and NL005 High Dose in Acute Myocardial Infarction, sponsored by Beijing Northland Biotech. Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-06-21.

Sponsored by Beijing Northland Biotech. Co., Ltd. · Phase 2, Interventional, and Basic science

How we know

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Jul 2022, registered Jul 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 196 studies in Myocardial Infarction with a site in China — 64 open to participants now, 73 under way, 8 of them phase 3. Myocardial Infarction · China.

Enrollment
89th of 107
90 · median 366
Started
2022
with 12 others
Phase 2
4 of 196
none open now
Registered
124th of 196
by date

Among the 196 studies in Myocardial Infarction with a site in China, this one is the 89th largest by enrollment of the 107 interventional ones that give a count, is one of 13 that started in 2022, is one of 4 in phase 2, and was the 124th registered.

Myocardial Infarction

2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

64 of the 196 studies in Myocardial Infarction with a site in China are open now. Recruiting first, the newest first:

59 more — sign in →

All 64 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 196 studies in Myocardial Infarction with a site in China, or all of them as a file.
02

Study summary

A multicenter randomized double-blind placebo parallel control design was used in this study. The 90 participants were randomly assigned to placebo, 0.5μg/kg dose group, and 1.0μg/kg dose group in a ratio of 1:1:1. After randomization, subjects received the trial drug or placebo intravenously within 12 hours and on days 2 to 7 after PCI. The patients were observed 90 days after PCI.

Read the detailed description

Cardiovascular magnetic resonance imaging (CMR) was performed on day 5 and day 90 after PCI to evaluate myocardial infarction size, microvascular obstruction area, left ventricular ejection fraction (LVEF), left ventricular end-systolic volume (LVESV), and left ventricular end-diastolic volume (LVEDV). Physical examination, blood routine examination, and coagulation function examination were performed before the first dose, on the 7th, 30th, and 90th day after PCI. The examination before the first dose was conducted to accept the examination results from the current onset to the first dose.Electrocardiogram (ECG) was performed before the first dose, day 2, day 7, day 30, and day 90 after PCI, and the test results from the period after PCI to the first dose were received. Vital signs were examined before the first dose, day 1 to day 7, day 30, and day 90 after PCI, and the results of the examination from the first onset to the first dose were accepted during the examination before the first dose. Blood biochemical tests were performed before the first dose, from day 2 to day 4, day 7, day 30, and day 90 after PCI. The results of the examinations from the first onset to the first dose were accepted during the examination before the first dose. High-sensitivity troponin I(hs-cTnI) or troponin I(cTnI) and amino-terminal B-type natriuretic peptide precursor (NT-proBNP) or B-type natriuretic peptide (BNP) were tested before first administration and on days 2, 3, 4, and 7 after PCI. Examination results from the time after PCI to the time before initial administration; Creatine kinase isoenzyme (CK-MB) tests were performed before the first dose, 12 hours after the first dose, day 2 (if it coincided with 12 hours after the first dose, no repeat blood collection was required), day 3, and day 4. The test results from the period after PCI to the period before the first dose were accepted. Tumor markers were detected and immunogenic blood samples were collected before the first dose and on the 30th day after PCI. The tumor markers were examined before the first dose. Urine routine examination was performed before the first dose and on the 90th day after PCI. The examination before the first dose accepted the examination results from the onset of the disease to the first dose. Drug combinations, adverse events, and cardiovascular events were recorded during the trial.

03

Conditions studied

  • Acute Myocardial Infarction

Keywords

  • CMR
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subjects or their guardians voluntarily participate in the experiment and sign the ;
  2. Age ≥18 years old and ≤75 years old, gender is not limited;
  3. STEMI patients with proximal or/and middle occlusion of a single left anterior descending artery (TIMI grade 0-1) and PCI;
  4. No coronary collateral (Rentrop grade 0);
  5. meet one of the following conditions:

    • The total myocardial ischemia time before PCI was \< 6 hours, and the TIMI grade after PCI was \< 3
    • 6 hours ≤ Total myocardial ischemia time before PCI ≤24 hours Note: Total myocardial ischemia time =PCI wire passage time - start time of chest pain
  6. All subjects (male and female) must agree to use appropriate methods (hormonal or barrier methods, abstinence) during study participation and up to 6 months of the last dosing, and women of childbearing age must test negative for pregnancy before dosing.

Exclusion criteria

Exclusion Criteria:

  1. Patients with a history of myocardial infarction who have received acute coronary thrombolysis, interventional therapy, or bypass surgery; A clear diagnosis of acute heart failure (Killip grade ≥III);
  2. Severe arrhythmias that cannot be corrected;
  3. Aortic dissection;
  4. Severe liver and kidney dysfunction or severe consumption;
  5. History of major surgery or hemorrhagic stroke within six months;
  6. Previous history of malignant tumors;
  7. Hypertensive patients with systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥110 mmHg after active antihypertensive treatment;
  8. allergic reaction history, especially mannitol, drugs, protein preparations, biological products;
  9. Patients who participated in other clinical studies within 3 months prior to screening;
  10. Can not perform CMR examination;
  11. Other conditions deemed unsuitable for inclusion by the investigators (for example, those whose coronary arteries other than the left anterior descending branch were judged by the investigators to require elective revascularization therapy at the same time or within 1 month).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    Middle Dose

    12 hours after PCI: 0.5 ug/kg Recombinant Human Thymosin β4 (intravenous injection),Day2-Day7 after PCI:0.5 ug/kg Recombinant Human Thymosin β4 (intravenous injection)

    Drug: NL005 Middle Dose

  • Experimental
    High Dose

    12 hours after PCI: 1.0 ug/kg Recombinant Human Thymosin β4 (intravenous injection),Day2-Day7 after PCI:1.0 ug/kg Recombinant Human Thymosin β4 (intravenous injection)

    Drug: NL005 High Dose

  • Placebo comparator
    Placebo

    Patients in this treatment group will receive placebo respective. Continuous administration for 7 days.

    Drug: Placebo

Interventions

  • DrugNL005 Middle Dose

    Patients in this treatment group will receive NL005 for 0.5 ug/kg respective.Continuous administration for 7 days.

    Also known as: NL005( Middle Dose)

  • DrugNL005 High Dose

    Patients in this treatment group will receive NL005 for 1.5 ug/kg respective.Continuous administration for 7 days.

    Also known as: NL005( High Dose)

  • DrugPlacebo

    30 subjects will be randomly assigned to the placebo for 7 days

06

What researchers measure

Primary outcomes

  1. Percentage change of myocardial infarction area

    The percentage of myocardial infarction area was defined as the percentage of CMR delayed enhancement area in the entire left ventricular myocardium as measured by plane geometry of computer-assisted enhanced myocardium.Percentage change of myocardial infarction size =D5 percentage of myocardial infarction size -D90 percentage of myocardial infarction size

    Time frame: Day 5、Day 90

Secondary outcomes

  1. Myocardial mass (g)

    Myocardial infarction area was defined as CMR delayed enhancement area, and myocardial mass (g) were calculated , and determined by plane geometry method of computer-aided enhanced myocardium. Myocardial infarction size change =D5 myocardial infarction size -D90 myocardial infarction size.

    Time frame: Day 5、Day 90

  2. Myocardial volume (ml)

    Myocardial infarction area was defined as CMR delayed enhancement area, and volume (ml) were calculated, and determined by plane geometry method of computer-aided enhanced myocardium.Myocardial infarction size change =D5 myocardial infarction size -D90 myocardial infarction size.

    Time frame: Day 5、Day 90

  3. Myocardial microvessel obstruction area change value

    Myocardial microvessel obstruction area change value =D5 microvessel obstruction area -D90 microvessel obstruction area

    Time frame: Day 5、Day 90

  4. The change of CK-MB before and after administration

    CK-MB change value = CK-MB value before administration - CK-MB value after administration

    Time frame: Before the first dose, 12 hours after the first dose, day 2, day 3, day 4

  5. The area under the CK-MB curve within 4 days

    CK-MB change value = CK-MB value before administration - CK-MB value after administration

    Time frame: Before the first dose, 12 hours after the first dose, day 2, day 3, day 4

  6. Changes of left ventricular ejection fraction (LVEF)

    Left ventricular ejection fraction (LVEF) change =D90 LVEF-D5 LVEF

    Time frame: Day 5、Day 90

  7. Changes of left ventricular end-systolic volume (LVESV)

    Left ventricular end-systolic volume (LVESV) change =D90 LVESV-D5 LVESV

    Time frame: Day 5、Day 90

  8. Changes of left ventricular end-diastolic volume (LVEDV)

    Left ventricular end-diastolic volume (LVEDV) change = D90 LVEDV-D5 LVEDV

    Time frame: Day 5、Day 90

07

Study locations

1 site
  • Fuwai Hospital, Chinese Academy of Medical Sciences
    Beijing, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in May 2023, 10 months.

Of 45 phase 2 interventional studies under Myocardial Infarction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 42. This study's 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2023
First posted
Aug 9, 2023
StartActual
Jul 15, 2022
Primary completionActual
May 26, 2023
CompletionActual
May 29, 2023
Last update
Jun 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05984134
Lead sponsor
Beijing Northland Biotech. Co., Ltd.
Responsible party
Sponsor
First posted
Aug 9, 2023
Start date
Jul 15, 2022
Primary completion
May 26, 2023
Completion
May 29, 2023
Last update
Jun 21, 2024

Study contacts

KeFei Dou
principal investigator · Chinese Academy of Medical Sciences, Fuwai Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion